A New Approach Methodology (NAM) for the Prediction of (Nor)Ibogaine-Induced Cardiotoxicity in Humans
Safety (cardiac & more) In vitro high
AI-extracted · unverified · confirm at source
PBK model predicts ibogaine QTc BMDL₁₀ of 97mg/70kg; noribogaine dominates in vivo cardiotoxicity due to high plasma levels and lower protein binding
Dosing: BMDL₁₀: 97 mg ibogaine / 70 kg (QTc onset); clinical range discussed: 420–2100 mg (6–30 mg/kg) (not-applicable)
Safety data present: QTC
Contraindications: Doses above BMDL₁₀ of ~97 mg ibogaine (70 kg body weight) predicted to cause significant QTc prolongation, CYP2D6 poor metaboliser status (up to 43-fold higher ibogaine concentrations), Concurrent CYP2D6 inhibitor use (26-fold higher ibogaine Cmax reported), Clinical doses (420–2100 mg) are 4–21-fold above predicted BMDL₁₀ for QTc prolongation